PL376837A1 - Pochodne imidazochinoliny jako ligandy receptora adenozyny A3 - Google Patents

Pochodne imidazochinoliny jako ligandy receptora adenozyny A3

Info

Publication number: PL376837A1
Authority: PL; Poland
Prior art keywords: adenosine; receptor ligands; imidazoquinoline derivatives; imidazoquinoline; derivatives
Prior art date: 2002-11-15

Application number

PL376837A

Other languages

English (en)

Inventor

Peter Aranyi

Laszlo Balazs

Maria Balogh

Sandor Batori

NAGY Lajos T.

Geza Timari

Kinga Boer

Zoltan Kapui

Endre Mikus

Katalin Gerber

Szeredi Judit Vargane

Katalin Urban-Szabo

Erzsebet Walcz

Original Assignee

Sanofi-Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-15

Filing date

2003-11-11

Publication date

2006-01-09

2003-11-11 Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis

2006-01-09 Publication of PL376837A1 publication Critical patent/PL376837A1/pl

Links

RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
102000008161 Adenosine A3 Receptor Human genes 0.000 title 1
108010060261 Adenosine A3 Receptor Proteins 0.000 title 1
239000003446 ligand Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Psychology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)

PL376837A 2002-11-15 2003-11-11 Pochodne imidazochinoliny jako ligandy receptora adenozyny A3 PL376837A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU0203976A HUP0203976A3 (en)	2002-11-15	2002-11-15	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number	Publication Date
PL376837A1 true PL376837A1 (pl)	2006-01-09

Family

ID=90001561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL376837A PL376837A1 (pl)	2002-11-15	2003-11-11	Pochodne imidazochinoliny jako ligandy receptora adenozyny A3

Country Status (34)

Country	Link
US (2)	US7419977B2 (pl)
EP (1)	EP1560828B9 (pl)
JP (1)	JP4533148B2 (pl)
KR (1)	KR20050088291A (pl)
CN (1)	CN1332960C (pl)
AR (1)	AR041968A1 (pl)
AT (1)	ATE325123T1 (pl)
AU (1)	AU2003282263B2 (pl)
BR (1)	BR0316355A (pl)
CA (1)	CA2505910C (pl)
CO (1)	CO5690577A2 (pl)
CY (1)	CY1105180T1 (pl)
DE (1)	DE60305058T2 (pl)
DK (1)	DK1560828T3 (pl)
EA (1)	EA007595B1 (pl)
ES (1)	ES2263039T3 (pl)
HR (1)	HRP20050540A2 (pl)
HU (1)	HUP0203976A3 (pl)
IL (1)	IL168516A (pl)
IS (1)	IS2456B (pl)
MA (1)	MA27501A1 (pl)
ME (1)	MEP19008A (pl)
MX (1)	MXPA05005198A (pl)
NO (1)	NO20052866D0 (pl)
NZ (1)	NZ540029A (pl)
PL (1)	PL376837A1 (pl)
PT (1)	PT1560828E (pl)
RS (1)	RS51320B (pl)
SI (1)	SI1560828T1 (pl)
TN (1)	TNSN05133A1 (pl)
TW (1)	TWI248934B (pl)
UA (1)	UA78889C2 (pl)
WO (1)	WO2004046146A1 (pl)
ZA (1)	ZA200503807B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0105406A3 (en) *	2001-12-21	2003-12-29	Sanofi Aventis	Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) *	2004-04-19	2006-02-28	Sanofi Aventis	Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
US20090088403A1 (en) *	2007-05-07	2009-04-02	Randy Blakely	A3 adenosine receptors as targets for the modulation of central serotonergic signaling
HUP0700395A2 (en) *	2007-06-07	2009-03-02	Sanofi Aventis	Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
US9199102B2 (en)	2009-07-21	2015-12-01	Oradin Pharmaceutical Ltd.	A3 adenosine receptor ligands for modulation of pigmentation
BR122021012629B1 (pt)	2013-02-01	2022-06-07	Wellstat Therapeutics Corporation	Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
KR101820909B1 (ko) *	2017-07-07	2018-01-23	퓨쳐메디신 주식회사	아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물
WO2019055877A1 (en)	2017-09-15	2019-03-21	Forma Therapeutics, Inc.	TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
IL279734B2 (en)	2018-06-29	2024-11-01	Forma Therapeutics Inc	Inhibiting creb binding protein (cbp)
EP3937936A4 (en) *	2019-03-15	2022-12-28	Forma Therapeutics, Inc.	INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
TW202102494A (zh)	2019-03-15	2021-01-16	美商弗瑪治療公司	抑制環amp-反應元件-結合蛋白(creb)
US11801243B2 (en)	2020-09-23	2023-10-31	Forma Therapeutics, Inc.	Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en)	2020-09-23	2023-10-24	Forma Therapeutics, Inc.	Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
BR112023011284A2 (pt)	2020-12-09	2024-02-06	Wellstat Therapeutics Corp	Composto de imidazoquinolina com atividade anti-inflamatória, antifúngica, antiparasítica e antineoplásica

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4075343A (en) *	1976-09-13	1978-02-21	Pfizer Inc.	Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
GB1596652A (en) *	1977-01-20	1981-08-26	Roussel Lab Ltd	Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives
SE441449B (sv)	1979-02-09	1985-10-07	Roussel Uclaf	Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat
FR2448541A1 (fr)	1979-02-09	1980-09-05	Roussel Uclaf	Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4644002A (en)	1979-02-09	1987-02-17	Roussel Uclaf	Imidazo[2,1-C]quinolines, useful as antiallergic agents
CA2336967C (en)	1998-07-10	2010-06-29	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	A3 adenosine receptor antagonists
US6448253B1 (en) *	1998-09-16	2002-09-10	King Pharmaceuticals Research And Development, Inc.	Adenosine A3 receptor modulators
JP4077198B2 (ja) *	1999-09-28	2008-04-16	株式会社大塚製薬工場	トリアゾロプリン誘導体、該誘導体を含有する医薬組成物およびアデノシンａ３受容体親和剤
US7160890B2 (en) *	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
BR0115847A (pt) *	2000-12-01	2004-02-25	Osi Pharm Inc	Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
EP1390349B1 (en)	2001-05-31	2012-07-25	Sanofi	Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
HUP0105407A3 (en) *	2001-12-21	2004-04-28	Sanofi Aventis	Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105406A3 (en)	2001-12-21	2003-12-29	Sanofi Aventis	Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

2002
- 2002-11-15 HU HU0203976A patent/HUP0203976A3/hu unknown
2003
- 2003-11-11 PT PT03773882T patent/PT1560828E/pt unknown
- 2003-11-11 DK DK03773882T patent/DK1560828T3/da active
- 2003-11-11 AU AU2003282263A patent/AU2003282263B2/en not_active Ceased
- 2003-11-11 SI SI200330299T patent/SI1560828T1/sl unknown
- 2003-11-11 EA EA200500830A patent/EA007595B1/ru unknown
- 2003-11-11 MX MXPA05005198A patent/MXPA05005198A/es active IP Right Grant
- 2003-11-11 RS YUP-2005/0364A patent/RS51320B/sr unknown
- 2003-11-11 BR BR0316355-5A patent/BR0316355A/pt not_active IP Right Cessation
- 2003-11-11 WO PCT/HU2003/000095 patent/WO2004046146A1/en not_active Ceased
- 2003-11-11 KR KR1020057008683A patent/KR20050088291A/ko not_active Abandoned
- 2003-11-11 EP EP03773882A patent/EP1560828B9/en not_active Expired - Lifetime
- 2003-11-11 HR HR20050540A patent/HRP20050540A2/xx not_active Application Discontinuation
- 2003-11-11 CA CA2505910A patent/CA2505910C/en not_active Expired - Fee Related
- 2003-11-11 DE DE60305058T patent/DE60305058T2/de not_active Expired - Lifetime
- 2003-11-11 JP JP2004552920A patent/JP4533148B2/ja not_active Expired - Fee Related
- 2003-11-11 CN CNB2003801062293A patent/CN1332960C/zh not_active Expired - Fee Related
- 2003-11-11 PL PL376837A patent/PL376837A1/pl not_active Application Discontinuation
- 2003-11-11 AT AT03773882T patent/ATE325123T1/de active
- 2003-11-11 UA UAA200505875A patent/UA78889C2/uk unknown
- 2003-11-11 NZ NZ540029A patent/NZ540029A/en not_active IP Right Cessation
- 2003-11-11 ES ES03773882T patent/ES2263039T3/es not_active Expired - Lifetime
- 2003-11-11 ME MEP-190/08A patent/MEP19008A/xx unknown
- 2003-11-14 TW TW092131901A patent/TWI248934B/zh not_active IP Right Cessation
- 2003-11-14 AR ARP030104200A patent/AR041968A1/es unknown
2005
- 2005-05-10 TN TNP2005000133A patent/TNSN05133A1/en unknown
- 2005-05-10 IL IL168516A patent/IL168516A/en not_active IP Right Cessation
- 2005-05-11 ZA ZA200503807A patent/ZA200503807B/en unknown
- 2005-05-16 US US11/130,429 patent/US7419977B2/en not_active Expired - Fee Related
- 2005-05-31 IS IS7874A patent/IS2456B/is unknown
- 2005-06-13 NO NO20052866A patent/NO20052866D0/no not_active Application Discontinuation
- 2005-06-13 MA MA28334A patent/MA27501A1/fr unknown
- 2005-06-14 CO CO05057645A patent/CO5690577A2/es not_active Application Discontinuation
2006
- 2006-07-28 CY CY20061101054T patent/CY1105180T1/el unknown
2008
- 2008-06-17 US US12/140,512 patent/US7709489B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IS2456B (is)	2008-11-15
AU2003282263A1 (en)	2004-06-15
MXPA05005198A (es)	2005-08-18
CN1332960C (zh)	2007-08-22
PT1560828E (pt)	2006-08-31
IS7874A (is)	2005-05-31
NO20052866L (no)	2005-06-13
JP2006515572A (ja)	2006-06-01
IL168516A (en)	2011-05-31
CO5690577A2 (es)	2006-10-31
MA27501A1 (fr)	2005-08-01
ATE325123T1 (de)	2006-06-15
JP4533148B2 (ja)	2010-09-01
EA200500830A1 (ru)	2005-10-27
TNSN05133A1 (en)	2007-05-14
CY1105180T1 (el)	2010-03-03
ES2263039T3 (es)	2006-12-01
US7419977B2 (en)	2008-09-02
TW200413369A (en)	2004-08-01
EA007595B1 (ru)	2006-12-29
SI1560828T1 (sl)	2006-08-31
ZA200503807B (en)	2006-08-30
US20050234056A1 (en)	2005-10-20
HRP20050540A2 (en)	2005-08-31
US7709489B2 (en)	2010-05-04
RS51320B (sr)	2010-12-31
RS20050364A (sr)	2007-08-03
HUP0203976A3 (en)	2004-08-30
NZ540029A (en)	2007-01-26
MEP19008A (en)	2010-06-10
DK1560828T3 (da)	2006-09-04
CN1726213A (zh)	2006-01-25
CA2505910A1 (en)	2004-06-03
KR20050088291A (ko)	2005-09-05
TWI248934B (en)	2006-02-11
EP1560828B1 (en)	2006-05-03
DE60305058D1 (de)	2006-06-08
WO2004046146A1 (en)	2004-06-03
CA2505910C (en)	2010-07-13
HU0203976D0 (en)	2003-01-28
UA78889C2 (en)	2007-04-25
EP1560828A1 (en)	2005-08-10
AU2003282263B2 (en)	2009-05-14
HUP0203976A2 (hu)	2004-07-28
NO20052866D0 (no)	2005-06-13
BR0316355A (pt)	2005-09-27
DE60305058T2 (de)	2006-12-14
US20080255110A1 (en)	2008-10-16
EP1560828B9 (en)	2007-02-14
HK1077819A1 (en)	2006-02-24
AR041968A1 (es)	2005-06-01

Legal Events

Date	Code	Title	Description
2013-04-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL196021A0 (en)	2009-02-11	Pyrazolopyridine derivatives uses
AP1850A (en)	2008-05-26	Spiroindolineplperidine derivatives
EG24050A (en)	2008-04-13	Heterocylocarboxamide derivatives
ZA200604352B (en)	2008-12-31	Azepinondole derivatives as pharmaceutical agents
PL373953A1 (pl)	2005-09-19	Pochodne 7-aminobenzotiazolu jako ligandy receptora adenozynowego
PL374718A1 (pl)	2005-10-31	Azolidynono-winylowe pochodne skondensowanego benzenu
IL166121A0 (en)	2006-01-15	Indole-3-sulphur derivatives
EP1522540A4 (en)	2011-08-10	AZAARENE DERIVATIVES
PL376475A1 (pl)	2005-12-27	Pochodne N-podstawionej 2-oksodihydropirydyny
IL166139A0 (en)	2006-01-15	1-heterocycylalkyl-3-sulfonylazaindole or- azaindazole derivatives as 5-hydroxytryptamine-6 ligands
IL166426A0 (en)	2006-01-15	N-biarylmethyl aminocycloalkanecarboxamide derivatives
PL369470A1 (pl)	2005-04-18	Pochodne benzotiazolu jako ligandy receptora adenozynowego
HRP20050540A2 (en)	2005-08-31	Imidazoquinoline derivatives as adenosine a3 receptor ligands
AU2003275838A8 (en)	2004-05-13	Pyrrolidin-2-on derivatives as ep4 receptor agonists
AU2003231805A8 (en)	2004-02-09	Purine derivatives as liver x receptor agonists
IL162444A0 (en)	2005-11-20	Triazolo-quinolin derivatives useful as adenosine receptor ligands
AU3167402A (en)	2002-06-24	Aminotriazolopyridiine derivatives as adenosine receptor ligands
AU2003222659A8 (en)	2003-11-03	23-o-substituted 5-o-mycaminosyltylonide derivatives
IL164311A0 (en)	2005-12-18	Compounds useful in preparing coamptothecin derivatives
SI1636223T1 (sl)	2008-06-30	Derivati benzotiazola kot ligandi receptorja adenozina
EP1531854A4 (en)	2006-06-28	O-DERIVATED NOCATHIACIN DERIVATIVES
GB0213488D0 (en)	2002-07-24	2-Naphthamide derivatives
AU2003304151A8 (en)	2005-01-21	Heteroaryl-ethanolamine derivatives as antiviral agents
AU2003243397A8 (en)	2003-12-19	Homo-camptothecin derivatives
GB0307377D0 (en)	2003-05-07	Ergoline derivatives